Matthew Schipper
机构: Professor of Radiation Oncology and Biostatistics, University of Michigan
主页: umich.edu
每年引用次数
引用次数
引用: 10,870
H-指数: 52
I10-指数 : 143
出版物: 427
Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.
Daniel E. Spratt , Shawn Malone , Soumyajit Roy , Scott Grimes
Journal of Clinical Oncology 39 ( 2) 136 -144
50
2021
Quantitative CT of lung nodules: Dependence of calibration on patient body size, anatomic region, and calibration nodule size for single- and dual-energy techniques
Mitchell M. Goodsitt , Heang-Ping Chan , Ted W. Way , Mathew J. Schipper
Medical Physics 36 ( 7) 3107 -3121
12
2009
Parotid glands dose-effect relationships based on their actually delivered doses: implications for adaptive replanning in radiation therapy of head-and-neck cancer.
Klaudia U. Hunter , Laura L. Fernandes , Karen A. Vineberg , Daniel McShan
International Journal of Radiation Oncology Biology Physics 87 ( 4) 676 -682
49
2013
Aspiration pneumonia after chemo-intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors.
Klaudia U. Hunter , Oliver E. Lee , Teresa H. Lyden , Marc J. Haxer
Head and Neck-journal for The Sciences and Specialties of The Head and Neck 36 ( 1) 120 -125
65
2014
A phase I/II trial of intensity-modulated radiation (IMRT) dose escalation with concurrent fixed- dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer
Edgar Ben-Josef , Mathew Schipper , Isaac R. Francis , Scott Hadley
International Journal of Radiation Oncology Biology Physics 84 ( 5) 1166 -1171
142
2012
Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer.
Amichay Meirovitz , Carol Anne Murdoch-Kinch , Mathew Schipper , Charlie Pan
International Journal of Radiation Oncology Biology Physics 66 ( 2) 445 -453
135
2006
Radioiodine Therapy and Graves' Ophthalmopathy
J. C. Sisson , M. J. Schipper , C. C. Nelson , J. E. Freitas
The Journal of Nuclear Medicine 49 ( 6) 923 -930
24
2008
131I-Tositumomab Radioimmunotherapy: Initial Tumor Dose–Response Results Using 3-Dimensional Dosimetry Including Radiobiologic Modeling
Y. K. Dewaraja , M. J. Schipper , P. L. Roberson , S. J. Wilderman
The Journal of Nuclear Medicine 51 ( 7) 1155 -1162
73
2010
Tumor-Absorbed Dose Predicts Progression-Free Survival Following 131I-Tositumomab Radioimmunotherapy
Y. K. Dewaraja , M. J. Schipper , J. Shen , L. B. Smith
The Journal of Nuclear Medicine 55 ( 7) 1047 -1053
27
2014
SBRT outcomes for primary and metastatic liver lesions.
M. H. Stenmark , E. Liu , M. J. Schipper , E. Ben-Josef
Journal of Clinical Oncology 29 262 -262
2
2011
Decreased Lung Perfusion After Breast/Chest Wall Irradiation: Quantitative Results From a Prospective Clinical Trial.
Adam L. Liss , Robin B. Marsh , Nirav S. Kapadia , Daniel L. McShan
International Journal of Radiation Oncology Biology Physics 97 ( 2) 296 -302
7
2017
High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer
S G Zhao , W C Jackson , V Kothari , M J Schipper
Prostate Cancer and Prostatic Diseases 18 ( 3) 229 -236
7
2015
Does Vascular Collapse Occur After Treatment of Hepatocellular Cancer With Stereotactic Body Radiation Therapy?
Theodore S Lawrence , Madhava P Aryal , Joseph R Evans , Kyle C Cuneo
International Journal of Radiation Oncology* Biology* Physics 117 ( 5) 1236 -1240
2023
Quantitative SPECT/CT for radioimmunotherapy (RIT) treatment planning: Comparison of tracer and therapy dosimetry
Mark Kaminski , Anca Avram , Matthew Schipper , Denise Regan
Society of Nuclear Medicine Annual Meeting Abstracts 50 377
1
2009
Tumor dose-response in I-131 radioimmunotherapy using measures from 3-dimensional calculation including radiobiologic modeling
Kenneth Koral , Scott Wilderman , Peter Roberson , Mark Kaminski
Society of Nuclear Medicine Annual Meeting Abstracts 51 304
2010
Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia.
Mark D. Iannettoni , Mark B. Orringer , Matthew Schipper , Lin Lin
Clinical Cancer Research 9 ( 13) 4819 -4825
123
2003
Image-based patient-specific absorbed dose to active marrow during radioimmunotherapy
Scott Wilderman , Peter Roberson , Mark Kaminski , Anca Avram
Society of Nuclear Medicine Annual Meeting Abstracts 55 49
2014
I-131 Radioimmunotherapy: Prediction of tumor level therapy absorbed dose from the tracer study via a mixed model fit of time-activity
Mark Kaminski , Anca Avram , Matthew Schipper , Yuni Dewaraja
Society of Nuclear Medicine Annual Meeting Abstracts 51 85
2010
Logistic regression models for accurate prediction of tumor control using radiobiologic dose metrics in Y-90 radioembolization
Peter Roberson , Matthew Schipper , Yuni Dewaraja , Theresa Devasia
The Journal of Nuclear Medicine 60 120 -120
2019
Response assessment during chemoradiation using a hypercellular/hyperperfused imaging phenotype predicts survival in patients with newly diagnosed glioblastoma.
Michelle M Kim , Yue Cao , Hemant A Parmar , Matthew Schipper
Neuro-oncology
2021